News at the Intersection of Mental Health and Technology
Good morning.
Today’s edition looks at an FDA pilot bringing AI-delivered talk therapy to Medicare, research on the social trade-offs of AI companionship, and a methodological debate over how mental-health apps should be evaluated.
What happened: The FDA’s TEMPO pilot program now includes an AI voice agent from Limbic Inc. to deliver cognitive behavioral therapy to Medicare patients, allowing its use before the agency has evaluated its effectiveness.
Key points:
Operating under ‘enforcement discretion,’ the pilot allows the FDA to waive certain premarket authorization requirements for participating devices.
The device is intended for depression or anxiety but is contraindicated for many common co-occurring conditions like substance use disorder.
Why this is important:
This development places Medicare patients in a position to receive treatment from an unreviewed AI, highlighting a regulatory trade-off between faster access to new technology and ensuring proven effectiveness before patient use.
What happened: Research in Psychology & Marketing found that emotionally intelligent AI companions can improve users’ psychological well-being while simultaneously decreasing their social well-being by reducing motivation for real-world human interactions.
Key points:
The study, based on university students, found these divergent effects were amplified when users interacted via augmented reality.
A user’s perceived closeness to the chatbot was identified as the key mechanism driving both the positive and negative outcomes.
Why this is important:
The findings highlight a trade-off in using AI for loneliness, where a tool may inadvertently deepen social isolation.
This suggests the design of such companions requires careful consideration of their social impact.
What the authors argue: Researcher Ashley D. Kendall and colleagues argue that a mental-health app’s failure to outperform another treatment does not necessarily mean the app is ineffective.
They say comparisons with treatment controls can obscure a different question: whether the app helps at all.
Leave a Reply